Inhibition of the cancer stem cell immune checkpoint SOAT1 suppresses regulatory T cell functions through a trans-cellular 20(S)-Hydroxycholesterol-GPR132 pathway in mice - PubMed
6 hours ago
- #SOAT1
- #Treg suppression
- #cancer immunotherapy
- SOAT1 is identified as a cancer stem cell (CSC) immune checkpoint.
- Pharmacological inhibition of SOAT1 with STK shows robust anti-tumor effects in multiple preclinical models with low toxicity.
- SOAT1 inhibition leads to the release of 20(S)-Hydroxycholesterol (20SOHC) from tumor cells.
- 20SOHC activates the GPR132 pathway in regulatory T cells (Treg), suppressing their functions.
- Enhanced dendritic cell and cytotoxic CD8+ T cell responses are observed following SOAT1 inhibition.
- STK treatment synergizes with anti-PD-1 or anti-CTLA-4 immune checkpoint blockade (ICB) therapy.
- SOAT1 inhibition is proposed as a promising strategy for advanced cancer immunotherapy.